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During in situ perfusion of rat liver stimulation of nerve bundles around hepatic artery and portal vein 
resulted in an increase of glucose output, a switch from lactate uptake to output and in a decrease of portal 
flow. These effects remained essentially the same during 3 stimulation periods at 20 min intervals; 
norepinephrine overflow, however, was strongly decreased uring the second and third period. The 
metabolic and hemodynamic effects were not correlated to norepinephrine overflow during repetitive 
stimulations and during stimulations in the presence of norepinephrine, phentolamine, propranolol or 
desipramine. 
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1. INTRODUCTION 
In intact animals pre-ganglionic stimulation of 
the splanchnic nerve [1-5] and post-ganglionic 
stimulation of the hepatic nerves [6-10] were 
found to increase glucose output by the liver in 
rabbit [1-4], cat [5-8], dog [5,9], pig [5], sheep [5] 
and man [10]. In perfused liver preparations pre- 
ganglionic [11] and post-ganglionic [12-15] nerve 
stimulation was also shown to enhance glucose 
output in toad [11], mouse [12] and rat [13-15]. 
The effects of hepatic nerves have been reviewed in 
[16,17]. In all of these studies the nerves were 
stimulated applying -20V for 0.5-2ms at 20Hz 
during a single period only ranging from 1-30 min; 
the effectiveness of repetitive nerve stimulation is 
unknown. 
The nerve-dependent i crease of glucose output 
was due predominantly to an cr-adrenergic activa- 
tion of glycogenolysis in the fed animal [12,13] and 
to an increase of gluconeogenesis in the fasted 
animal [15]. During peripheral adrenergic neuro- 
transmission norepinephrine released into the 
synaptic left appears in part in the venous blood 
of the innervated organ; this transmitter overflow 
has been studied mainly in the spleen, heart and 
colon [18]. Norepinephrine overflow from the liver 
after stimulation of hepatic nerves has been studied 
so far only in the anaesthetized dog [19]. In this in- 
vestigation orepinephrine overflow was measured 
only at one time point (i.e., in a cumulative man- 
ner); the kinetics of the process were not reported. 
It was the object of this study to investigate in 
the perfused liver the metabolic effectiveness of 
repetitive nerve stimulations, the kinetics of 
norepinephrine overflow and the possible correla- 
tion between metabolic effects and overflow. It 
was found that the change of glucose and lactate 
output from livers of fed rats and the reduction of 
blood flow remained essentially the same during 
three 5 min periods of stimulation at 20 min inter- 
vals, while the overflow of norepinephrine was 
strongly decreased uring the second and third 
stimulation period. Apparently the metabolic and 
hemodynamic effects of the hepatic nerves were 
not correlated to norepinephrine overflow. 
2. MATERIALS AND METHODS 
All chemicals were reagent grade and from com- 
mercial sources. Enzymes were purchased from 
Boehringer (D-6800 Mannheim); bovine serum 
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albumin from Serva (D-6900 Heidelberg); and S- 
[3H]adenosylmethionine (SAM) from Amers- 
ham-Buchler (D-3300 Braunschweig). Norepine- 
phrine was supplied by Fluka (CH-9470 Buchs); 
propranolol by Rhein-Pharma (D-683 1 Planck- 
stadt); phentolamine and desipramine were a gift 
from Ciba-Geigy (D-7867 Wehr). 
cased-phosphate dehydrogenase (EC 1.1.1.49) and 
lactate dehydrogenase (EC 1.1.1.27), respectively. 
Norepinephrine was quantitated radiochemically 
[20] after enzymatic methylation with [3H]SAM, 
conversion to [3H]normetanephrine and separation 
by thin-layer chromatography. 
Male Wistar rats (130- 160 g) were kept on a 12 h 
day-night rhythm, 7-19h, with free access to 
food, standard diet 1320 of Altromin (D-4937 
Lage). Experiments were started at 9.30h. The 
technique of the in situ perfusion with media con- 
taining 5 mM glucose, 2 mM lactate, erythrocytes, 
bovine serum albumin and Krebs-Ringer bicar- 
bonate buffer and of the perivascular nerve 
stimulation (2OV, 2 ms, 20 Hz) has been described 
in [13]. 
3. RESULTS 
Glucose and lactate concentrations were measur- 
ed photometrically with standard enzymatic 
methods using hexokinase (EC2.7.1.1) plus glu- 
Rat liver was perfused without recirculation of- 
fering 5 mM glucose and 2 mM lactate for 40 min. 
Perivascular nerve stimulation for the next 5 min 
resulted in an increase of glucose output, in a 
switch from lactate uptake to output, in a decrease 
of portal flow and in the overflow of norepine- 
phrine (fig. 1). Epinephrine or dopamine were not 
found in the perfusate. Peak values were reached 
for glucose and lactate release after 4 min, for the 
flow change after 2 min and for norepinephrine 
release after 45 s. Thus, neurotransmitter overflow 
Lactate 
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Fig. 1. Substrate exchange, portal flow and norepinephrine overflow during repetitive lectrical nerve stimulation i  the 
rat liver perfused in situ. Hatched columns represent periods of stimulation. Values are means k+SEM of 4 expt. 
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was by far the fastest effect caused by nerve 
stimulation. 
During a second and third stimulation period 
after 65 min and 90 min of perfusion, respectively, 
the same alterations of substrate exchange and of 
portal flow, slightly diminished to 70-85%, were 
observed; yet norepinephrine overflow was clearly 
reduced to -20% (fig. 1). Apparently, the meta- 
bolic and hemodynamic nerve effects were not cor- 
related to neurotransmitter overflow. 
The diminished norepinephrine overflow during 
the repetitive stimulations may be caused by a par- 
tial depletion of the neurotransmitter in the hepatic 
nerve endings, where its level is the resultant of 
release into and uptake, respectively reuptake from 
the synaptic cleft, of de novo synthesis and 
degradation. There could have been no uptake in 
the periods before and after stimulations ince nor- 
epinephrine was absent from the synthetic perfu- 
sion‘ medium. Therefore, norepinephrine in a 
physiological concentration (5 nM) [21], which by 
itself was ineffective, was infused to allow uptake. 
However, norepinephrine overflow during the se- 
cond and third stimulations was diminished to the 
same extent in the presence as in the absence of cir- 
culating norepinephrine (not shown). Presumably 
norepinephrine could not be taken up under the 
conditions used or norepinephrine depletion was 
not the cause for diminished overflow during 
repetitive nerve stimulations. 
The apparent lack of correlation between the 
nemotransmitter overflow and the metabolic and 
hemodynamic nerve effects was further cor- 
roborated in experiments using a sympathetic 
agonist, an CY- and P-antagonist and reuptake in- 
hibitor (table 1). In the presence of all these agents 
the kinetics of the overflow were very similar to 
those of the control experiment, yet different peak 
values were reached (fig. 2). The agonist norepine- 
phrine increased glucose output slightly, yet reduc- 
ed neurotransmitter overflow. The a-antagonist 
phentolamine abolished the metabolic and hemo- 
Table 1 
Substrate exchange, portal flow and norepinephrine overflow following electrical nerve stimulation in the presence of 
adrenergic agonists, antagonists and reuptake inhibitors in the rat liver perfused in situ 
Conditions Increase in output of Decrease in Norepinephrine 
Glucose Lactate 
(&mol (C6). min-’ . g liver-‘) 
portal flow 
(ml.min-‘. 
g liver-‘) 
overflow 
(pmol.min-‘. 
g liver-‘) 
Control 1.07 0.53 0.56 so.35 
1st stimulation (* 0.07) (k 0.06) (* 0.07) (k2.89) 
Control 0.88 0.48 0.48 11.29b 
3rd stimulation (* 0.12) (* 0.05) (kO.11) (+ 3.65) 
Agonist 1.36 0.60 0.60 34.91= 
norepinephrine (& 0.27) (+- 0.07) (* 0.07) 
a-Antagonist O.lsb 
(* 7.31) 
0.09b 0.07b 10s.7sa 
phentolamine (* 0.05) (* 0.04) (* 0.03) (+ 32.67) 
P-Antagonist 0.89 0.48 0.52 30.93b 
propranolol (kO.11) (kO.11) (+ 0.06) (+ 1.78) 
Reuptake inhibitor 2.11b 0.49 0.56 77.43a 
desipramine (2 0.29) (k 0.06) (* 0.02) (? 12.95) 
Calcium- 0.02b 0.03b 0.03b 0.76b 
poor (+ 0.01) (+ 0.03) (* 0.03) (kO.71) 
Electrical stimulation of perivascular nerve bundles was performed for S min starting 40 min after the onset of perfusion. 
The effecters were added and omitted (calcium) at the start of the experiment (0 min), respectively. Final concentrations 
were 5 nM norepinephrine, 50pM phentolamine, 1OpM propranolol and I,uM desipramine. The metabolic, 
hemodynamic and overflow values represent he difference between the basic and the peak values (see fig. 1). Values 
are means + SEM given in parentheses of 3 expt each except for the control and norepinephrine which were 4 each. 
Student’s f-test: aP < 0.05; bP < 0.01 
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Fig. 2. Kinetics of norepinephrine overflow after nerve 
stimulation in the presence of adrenergic antagonists and 
a reuptake inhibitor in the rat liver perfused in situ. The 
hatched column represents the period of stimulation. 
Values are means of 3 expt each; the SEM is not shown 
to improve legibility of the figure, it is given for the peak 
values in table 1. For further experimental information 
see also table 1. 
Abbreviations: CYBA, a-blocking agent (phentolamine); 
,fJ-BA, &blocking agent (propranolol); DMI, desipra- 
mine (reuptake inhibitor) 
dynamic nerve effects but increased the overflow. 
The P-antagonist propranolol had no effects on the 
metabolic and hemodynamic parameters, yet the 
neurotransmitter overflow was reduced. Finally, 
the reuptake inhibitor desipramine clearly increas- 
ed the nerve-dependent glucose output, left the lac- 
tate exchange and the flow reduction unaltered and 
enhanced the overflow. With a calcium-poor 
medium (overall level 5 300~moM) nerve stimula- 
tion did neither elicit a change of the substrate 
balance and of the portal flow nor any norepine- 
phrine overflow. 
4. DISCUSSION 
Here we show that repetitive stimulation of the 
hepatic nerves resulted in essentially the same in- 
crease of glucose and lactate output and decrease 
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of portal flow (fig. 1). Apparently, even during 120 
min perfusion including 15 min neurostimulation, 
the functional neurotransmitter content in the 
hepatic nerve endings was kept over the level re- 
quired for normal signal propagation, although 
with the amino acid and neurotransmitter free 
medium used, replenishment by synthesis or by up- 
take was unlikely or even impossible. Both the 
metabolic and hemodynamic effects showed an 
‘escape’ phenomenon [22], in that the maximal 
changes reached could not be maintained in spite 
of a continued neurostimulation. After a 20 min 
interval the liver was no longer refractory to 
another stimulation period. The mechanism of the 
development and disappearance of this refrac- 
toriness is not understood. 
Stimulation of hepatic nerves was accompanied 
by an overflow of norepinephrine, which was 
clearly diminished during the second and third 
stimulation period, although the metabolic and 
hemodynamic effects remained the same (fig. 1). If 
the neurotransmitter overflow is proportional to 
release [ 13,181, the finding indicates that at least 
during the first stimulation period but possibly also 
during the second and third period more neuro- 
transmitter was released than required for signal 
transmission. 
During all consecutive stimulation periods (fig. 
1) and during the stimulation in the presence of the 
sympathetic agonist, the (Y- and P-antagonist and 
the reuptake inhibitor, overflow of norepinephrine 
was progressively reduced after an initial peak with 
the same kinetics (fig. 2). This phenomenon, term- 
ed ‘depletion response’, has been observed also 
during sustained sympathetic stimulation of the 
heart in anaesthetized ogs [24,25]. It might be due 
‘to negative feedback inhibition of release via pre- 
synaptic a2-receptors [26]. However, the unaltered 
depletion kinetics during blockade of a-receptors 
with phentolamine are at variance with this 
possibility.The phenomenon might also be caused 
by a gradual increase of neurotransmitter re- 
uptake. Yet, the unchanged overflow kinetics in the 
presence of the reuptake inhibitor desipramine do 
not support this mechanism. Furthermore, it has 
been postulated that most of the norepinephrine in 
the nerve endings is contained in a storage pool and 
that only a minor part is in a secretory pool, which 
is depleted rapidly upon nerve stimulation, but 
replenished rather slowly from the storage pool 
Volume 149, number 2 FEBS LETTERS November 1982 
[25]. The present findings are not in contradiction 
to the ‘two pools’ proposal, but they do not prove 
it. 
Finally, it was found that under a variety of con- 
ditions the metabolic and hemodynamic nerve ef- 
fects were not correlated to norepinephrine over- 
flow (table 1). Neurotransmitter overflow alone 
was in accord with expectations [ 18,231: It was 
decreased by the a-agonist norepinephrine and in- 
creased by the a-antagonist phentolamine; both 
can be explained by the negative feedback of 
release via pre-synaptic a-receptors. It was decreas- 
ed by the &antagonist propranolol, which in- 
dicates a blockade of the positive feedback of 
release via pre-synaptic &receptors. It was increas- 
ed by desipramine, which shows that reuptake is 
involved in the complex events leading to overflow. 
It was completely suppressed at low calcium con- 
centrations, which is in line with the calcium re- 
quirement of the release process in [27,28]. It thus 
remained open how the metabolic and hemody- 
namic nerve effects are quantitatively linked to the 
synaptic neurotransmission. Maybe the cotrans- 
mitter to norepinephrine which is not known in this 
system [ 191 plays a key role. 
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